FDA looks at pulling speedy approvals for three cancer drugs
pharmaphorum
APRIL 27, 2021
On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively.
Let's personalize your content